Unusual 11 Mid-Day Movers 10/14: CHIO, ACPW, JADE, CNO Higher; CXM, HILL, UCBH, UPI Lower
China INSOnline Corp. (NASDAQ: CHIO) 40% HIGHER; reports FY09 EPS of $0.23, compared to $0.25 in the same quarter last year. Revenue for the fiscal year was $17.9 million, versus $13.7 million in FY08.
Active Power, Inc. (NASDAQ: ACPW) 35.2% HIGHER; today announced it has received a second multimillion dollar order from one of the world's largest Internet search engine providers for more than 16 megawatts of its CleanSource UPS (uninterruptible power supply) systems.
LJ International Inc. (NASDAQ: JADE) 27.4% HIGHER; sees Q3 sales over $25 million and EPS of $0.03-$0.05. Sales at this level would represent a 22% drop in sales from the $32.9 million reported in the same quarter last year. Meanwhile, LJ reported earnings of $0.02 in Q308. As expected, the 40% decrease in wholesale revenues was due to the ongoing recession in the U.S. The decline is expected to be offset by an approximate 25% increase in revenues from the Company's ENZO division to over $11 million.
Conseco, Inc. (NYSE: CNO) 27.1% HIGHER; announced today that, as part of a series of transactions intended to enhance its capital position, it entered into a stock and warrant purchase agreement with John Paulson's Paulson & Co. Inc., on behalf of the several investment funds and accounts managed by it, to sell to Paulson 16.4 million shares of common stock and warrants to purchase 5.0 million shares of common stock for an aggregate purchase price of $77.9 million. Click here for the full report.
Cardium Therapeutics (AMEX: CXM) 26.5% LOWER; today announced plans for the commercial development of a new product candidate Excellagen, a collagen-based topical gel for use by physicians in conjunction with surgical debridement of wounds in patients with chronic or non-chronic diabetic foot ulcers. Click here for the full report.
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) 21% HIGHER; announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (Zymafos, ZIO-201). Palifosfamide is used in the treatment of patients with unresectable or metastatic soft tissue sarcoma.
Dot Hill Systems (Nasdaq: HILL) 15% LOWER; prior to today's move lower, shares of Dot Hill had rallied 8 straight days, gaining 34.5% over the course. Nothing wrong with a little profit taking...
Cepheid (Nasdaq: CPHD) 12.5% HIGHER; Needham & Co upgrades from Hold to Buy. Price target $17.
UCBH Holdings (Nasdaq: UCBH) 11.3% LOWER; continues to trade with extreme volatility. The stock seems to be correcting following a 10% rise yesterday.
Uroplasty Inc. (AMEX: UPI) 10.8% LOWER; up more than 60% in the last 3 trading sessions. Last night, the NYSE contacted Uroplasty in view of the unusual market activity in the company's stock. The company stated that its policy is not to comment on unusual market activity.
MannKind (Nasdaq: MNKD) 9.7% LOWER; Hapoalim Securities initiates coverage on with a Sell rating and a $1 price target.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
Active Power, Inc. (NASDAQ: ACPW) 35.2% HIGHER; today announced it has received a second multimillion dollar order from one of the world's largest Internet search engine providers for more than 16 megawatts of its CleanSource UPS (uninterruptible power supply) systems.
LJ International Inc. (NASDAQ: JADE) 27.4% HIGHER; sees Q3 sales over $25 million and EPS of $0.03-$0.05. Sales at this level would represent a 22% drop in sales from the $32.9 million reported in the same quarter last year. Meanwhile, LJ reported earnings of $0.02 in Q308. As expected, the 40% decrease in wholesale revenues was due to the ongoing recession in the U.S. The decline is expected to be offset by an approximate 25% increase in revenues from the Company's ENZO division to over $11 million.
Conseco, Inc. (NYSE: CNO) 27.1% HIGHER; announced today that, as part of a series of transactions intended to enhance its capital position, it entered into a stock and warrant purchase agreement with John Paulson's Paulson & Co. Inc., on behalf of the several investment funds and accounts managed by it, to sell to Paulson 16.4 million shares of common stock and warrants to purchase 5.0 million shares of common stock for an aggregate purchase price of $77.9 million. Click here for the full report.
Cardium Therapeutics (AMEX: CXM) 26.5% LOWER; today announced plans for the commercial development of a new product candidate Excellagen, a collagen-based topical gel for use by physicians in conjunction with surgical debridement of wounds in patients with chronic or non-chronic diabetic foot ulcers. Click here for the full report.
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) 21% HIGHER; announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (Zymafos, ZIO-201). Palifosfamide is used in the treatment of patients with unresectable or metastatic soft tissue sarcoma.
Dot Hill Systems (Nasdaq: HILL) 15% LOWER; prior to today's move lower, shares of Dot Hill had rallied 8 straight days, gaining 34.5% over the course. Nothing wrong with a little profit taking...
Cepheid (Nasdaq: CPHD) 12.5% HIGHER; Needham & Co upgrades from Hold to Buy. Price target $17.
UCBH Holdings (Nasdaq: UCBH) 11.3% LOWER; continues to trade with extreme volatility. The stock seems to be correcting following a 10% rise yesterday.
Uroplasty Inc. (AMEX: UPI) 10.8% LOWER; up more than 60% in the last 3 trading sessions. Last night, the NYSE contacted Uroplasty in view of the unusual market activity in the company's stock. The company stated that its policy is not to comment on unusual market activity.
MannKind (Nasdaq: MNKD) 9.7% LOWER; Hapoalim Securities initiates coverage on with a Sell rating and a $1 price target.
To get this report daily visit http://www.streetinsider.com/entities/Unusual+11+Mid-Day+Movers.
You May Also Be Interested In
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Needham & Company, Paulson & Co. (PCI), Unusual 11 Mid-Day MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
